Aktis Oncology starts Phase 1b trial for prostate cancer drug AKY-2519

May 4, 2026 4:05 PM

Aktis Oncology Inc. (NASDAQ: AKTS) announced the initiation of a Phase 1b clinical trial for AKY-2519, a B7-H3 miniprotein radioconjugate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found